Stock Screener
Stock Research
Market Indexes
Precious Metals
Energy
Commodities
Exchange Rates
Interest Rates
Economy
Global Metrics

CytomX Therapeutics Net Worth 2014-2022 | CTMX

Interactive chart of historical net worth (market cap) for CytomX Therapeutics (CTMX) over the last 10 years. How much a company is worth is typically represented by its market capitalization, or the current stock price multiplied by the number of shares outstanding. CytomX Therapeutics net worth as of March 23, 2023 is $0.11B.
  
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $0.115B $0.070B
CytomX Therapeutics, Inc. is an oncology focused biopharmaceutical company. The Company is engaged in developing Probody(TM) therapeutics for the treatment of cancer. Its pipeline focuses areas consist of Precision cancer immunotherapy and Probody drug conjugates. CytomX Therapeutics, Inc. is headquartered in South San Francisco, California.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $141.122B 8.73
GSK (GSK) United Kingdom $75.233B 9.43
Bio-Rad Laboratories (BIO.B) United States $13.735B 32.61
QIAGEN (QGEN) Netherlands $10.461B 19.38
Ginkgo Bioworks Holdings (DNA) United States $2.529B 0.00
Arcus Biosciences (RCUS) United States $1.165B 0.00
Biohaven (BHVN) United States $0.882B 0.00
Emergent Biosolutions (EBS) United States $0.391B 0.00
ADC Therapeutics SA (ADCT) Switzerland $0.153B 0.00
Enzo Biochem (ENZ) United States $0.102B 0.00
SQZ Biotechnologies (SQZ) United States $0.018B 0.00
Gelesis Holdings (GLS) United States $0.011B 0.00